Related Experiment Videos
Pathophysiologic and pharmacotherapy considerations in the management of the black hypertensive patient
1Department of Medicine, University of North Carolina, Chapel Hill.
Insights
Hypertension disproportionately affects Black individuals, leading to higher rates of kidney damage and heart disease. Treatment strategies must be reevaluated to address unique risks and improve outcomes in this population.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Pharmacology
Background:
- Hypertension-related diseases exhibit significantly higher mortality and morbidity in Black individuals compared to White individuals.
- Renal damage incidence is notably higher in Black populations, potentially 18 to 20 times greater than in White populations.
- Coronary heart disease prevalence and mortality trends in Black individuals require further investigation, as data suggests it may not be declining.
Purpose of the Study:
- To highlight the disparities in hypertension-related diseases among Black individuals.
- To explore the contributing factors to increased disease burden in Black populations.
- To advocate for a reevaluation of current hypertension treatment strategies in Black patients.
Main Methods:
- Review of existing epidemiological and clinical data on hypertension in Black populations.
- Analysis of factors contributing to increased susceptibility and severity of hypertension.
- Assessment of current treatment modalities and their efficacy in Black individuals.
Main Results:
- Increased prevalence and severity of hypertension in Black individuals.
- Potential increased susceptibility to end-organ damage.
- Socioeconomic factors and outdated treatment approaches may impede effective hypertension control.
Conclusions:
- Current hypertension management in Black individuals may be suboptimal due to a focus on blood pressure numbers over individual risk factors.
- Diuretic therapy's impact on lipid levels and left ventricular hypertrophy needs careful assessment.
- Pharmacotherapeutic approaches, such as beta-blockers (e.g., metoprolol), show promise but require consideration of specific population characteristics.
Abstract:
The mortality and morbidity of hypertension-related diseases among blacks are much higher than in age- and sex-matched white counterparts. New data show that the incidence of renal damage may be 18 to 20 times greater in blacks than in whites. Some preliminary data also indicate that coronary heart disease is much more prevalent in blacks than previously suspected and that coronary heart disease mortality among blacks may indeed not be declining, as it is for white populations. Major contributors to these findings in blacks are an increased prevalence and severity of hypertension, a possibly increased susceptibility to end-organ damage, socioeconomic factors and beliefs that affect hypertension control, and very possibly some obsolete treatments that focus on blood pressure numbers and do not emphasize the black person and the associated risk factors. Diuretic therapy has long been the mainstay treatment for black hypertensives, but the effects of diuretics on lipid levels and left ventricular hypertrophy, among other factors, should be carefully assessed. A recent study of beta-blockers in blacks showed that metoprolol was effective and well tolerated. Consideration of epidemiologic, pathophysiologic, and pharmacotherapeutic features of hypertension in blacks may require traditional views of this disease and its treatment in this special population to be reevaluated.